cse: neon · 2021. 2. 4. · on may 21, 2020, mind medicine (mindmed) inc. announced that it had...

neonmindbiosciences.comneonmindbiosciences.comCSE: NEON • OTC: NMDBF • FRA: 6UF

DEVELOPING INNOVATIVE TREATMENTS AND PRODUCTS TO TACKLE OBESITY AND PROMOTE HEALTH & WELLNESS

This presentation contains "forward looking information" within the meaning of applicable Canadian securities legislation. Wherever possible, words such as "plans", "expects", or "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, have been used to identify forward looking information.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of NeonMind Biosciences Inc. (“NeonMind”, “us” “we”) to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Forward looking statements are based on the reasonable assumptions, estimates, analysis and opinions of our management made in light of their experience and their perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Management believes that the assumptions and expectations reflected in such forward looking statements are reasonable.

FORWARD LOOKING INFORMATION

CSE: NEON • OTC: NMDBF | 2

3

NeonMind Biosciences is an integrated psychedelic drug development and wellness company focused on therapeutics uses of psychedelics to address public health needs including obesity, weight management and mental health

INVESTMENT HIGHLIGHTS• Focused on psychedelic drug development program within unique

indication – obesity and weight management

• Positive Pre-Clinical data supports pursuit of two parallel development tracks: low dose and high dose psilocybin therapeutics

• Establishing NeonMind-branded specialty mental health clinics to capitalize on psychedelic-based treatments for mental health disorders

• Near-term revenue opportunities with exciting consumer product launches in high growth functional food markets

• Led by seasoned management team with expertise in establishing access and adoption of novel treatments including drug development and commercial deployment


4

NEONMIND AT A GLANCE


PSYCHEDELIC RESEARCH DIVISION

●Proprietary asset; only player in massive unaddressed medical need

●Engaged in drug development research for the potential therapeutic uses of psychedelic compounds

●Advancing two psilocybin drug development programs targeting obesity

●Extensive US and international patent applications pending, covering the spectrum of weight management conditions

MEDICAL SERVICES DIVISION

● Early exposure to high growth transformational medical market

● Expected to announce initial NeonMind-branded specialty mental health clinics in Canada in 2021

● Integrated services platform to deliver evidence-backed, innovative treatments for mental health tailored to local market needs

● Enabling NeonMind to capture the potential success of the growing pipeline of psychedelic-based therapeutics across the mental health industry

CONSUMER PRODUCTS DIVISION

● Stable, near-term existing market

● Using proprietary formulations to develop and commercialize functional food products infused with non-psychoactive mushrooms

● Initial launch in Canadian market, introducing select e-commerce offerings in the U.S.

● Global rights holder to a robust catalogue of functional mushroom formulations to promote health and wellness

5

MARKET OPPORTUNITY – GLOBAL DEMAND FOR WEIGHT MANAGEMENT IS MASSIVE

1. WHO 2020, Obesity and Overweight. 2. Research and Markets 2017. 3. Novo Nordisk investor presentations. 4. FDA Drug Database. 5. Evaluate Vantage 2020.

MASSIVE GLOBAL MARKET FOR WEIGHT MANAGEMENT2

WEIGHT MANAGEMENT CONTINUES TO BE A GLOBAL HEALTH ISSUE1

LIMITED OPTIONS AND PAUCITY OF INNOVATION4,5

VS


13% of Adults Considered Obese

1.9BOverweight

650MObese US $245B by 2022

Estimated Annual Spend on Products and Services

31% CAGRGlobal Anti-Obesity

Drug Market

7% CAGRGlobal Weight

Management Market

Only 5 Drugs ApprovedFor Long-term use in the US

Only 1 Drug Candidate in Phase 3

STRONG GROWTH TRENDS IN ANTI-OBESITY DRUG MARKET: OUTPACING OVERALL MARKET2,3

6

WE ARE FOCUSED ON DEVELOPING PSYCHEDELIC-BASED THERAPEUTICS TO TREAT OBESITY

● We are one of two companies working on developing psilocybin into a prescription drug for weight management

● Patent portfolio provides protection for therapeutic use of psilocybin and derivatives for weight management

● Preclinical data to support drug development and bolster patent portfolio

● Management experience in drug development and commercialization

ObesityNeurology

Addiction

Psychiatry

PSYCHEDELIC RESEARCH DIVISION


7

CURRENT OPTIONS ARE NOT SUFFICIENT - PSYCHEDELICS OFFER A NEW OPPORTUNITY

PharmacotherapyAvg. 4% to 9% weight loss

Bariatric SurgeryAvg. 13% - 40% weight loss5

1. Apovian 2015, JCEM. 2. Wharton 2020, CMAJ. 3. Data from pivotal clinical studies of FDA approved anti-obesity drugs. 4. Lemstra 2016, Patient Pref Adherence. 5. Maciejewski 2017, JAMA Surg.

OBESITY TREATMENT REQUIRES A MULTIMODAL APPROACH1,2

01

02

WEIGHT LOSS IS NOT EASYAND EFFICACY IS LOW3,4

PSYCHEDELICS MAY ENHANCE TREATMENT MODALITIES

Psychological and Behavioral Therapy

Psychological and Behavioral Therapy

Pharmacotherapy

30% Drop OutWeight Regain is a Major Issue

Only 4 – 9% Weight LossPharmacotherapy with Diet and Exercise

Fundamental to treatment are lifestyle changes evoked by psychological and behavioral therapy

Diet and ExerciseAvg. 0% to 6% weight loss


8

PURSUING TWO TREATMENT PATHS SUPPORTED BY REPUTABLE SCIENTIFIC EVIDENCE

• Product Candidate: low dose psilocybin

• MOA: target 5-HT2C receptor to induce satiety without hallucinogenic effects

• Use: routinely to mitigate appetite throughout the program

• Treatment Delivery: physician prescription and pharmacy dispensing

• Clear Clinical Pathway: FDA guidance document on “Developing Products for Weight Management”5

• Supportive Pre-Clinical Data: NeonMind’s proprietary animal data supports psilocybin in reducing weight gain

TRADITIONAL DRUG THERAPY

• Product Candidate: high dose psilocybin

• MOA: target 5-HT2A receptor to induce hallucinogenic effect

• Use: during psychotherapy sessions using proprietary treatment protocol to induce lasting lifestyle changes

• Treatment Delivery: in-clinic, overseen by health professionals

• Building On Longstanding Practice to Enhance Results: Psychotherapy is routine and fundamental to weight management treatment

• Promising New Treatment Modality Enhancement1,2,3: Favorable DEP study results from renowned groups recognized by regulatory bodies with Breakthrough Designation

DRUG ENHANCED PSYCHOTHERAPY (DEP)

1. Davis 2020, JAMA Network. 2. Kaertner 2021, Sci Rep. 3. Smigielski 2019, Sci Rep. 4. Kumar 2015, Obesity. 5. FDA 2018, Developing Products for Weight Management Rev1. CSE: NEON • OTC: NMDBF | 8

9

PSILOCYBIN: MULTIFACETED MOLECULE WITH MULTIPLE OPPORTUNITIES TO ADDRESS OBESITY

Psilocybin1(and derivatives)

5-HT2A Receptor 5-HT2C Receptor

• Involved in hallucinogenic effect of psychedelics

• Drug target in exciting field of drug enhanced psychotherapy (DEP) to treat cognitive behavioral disorders including eating disorders2,3

• Involved in appetite control; when engaged induces an anorectic effect causing a loss of appetite

• Drug target of previous FDA approved prescription drug for obesity

1. Nichols 2016, Pharmacol Rev. 2. Reiff 2020, Am J Psychiatry. 3. Vollenweider 2020, Nat Rev Neurosci. CSE: NEON • OTC: NMDBF | 9

10

NEONMIND’S PROPRIETARY ANIMAL DATA SUPPORTS PSILOCYBIN EFFICACY IN REDUCING WEIGHT GAIN

• Psilocybin reduced weight gain by 31 and 28% for low and high dose respectively relative to placebo

• Significant reduction in weight gain was seen by day 3 for high dose and day 4 for low dose

• Novel data bolsters patent applications

● Method: Male rats were fed unlimited high calorie diet for 5 days with randomization to low dose (5mg/kg)(n=7) or high dose (20 mg/kg) (n=7) or placebo(n=12) on day one. Rats were weighed daily to measure weight gain.


Cumulative Weight Gain (from beginning of study)

1. Data on file NeonMind Biosciences

11

Formulation Indication MOA Preclinical Phase I Phase 2 Phase 3 Ongoing Work Next Milestone IP

High Dose Psilocybin

Drug Enhanced Psychotherapy

Weight Management 5-HT2A

Regulatory Package

Design of Phase 2 ProtocolPre-IND

US Provisional and PCT

Applications Filed

Low Dose Psilocybin

Drug Therapy

Weight Management

5-HT2CRegulatory Package

Animal Studies Pre-IND

US Provisional and PCT

Applications Filed

DEVELOPMENT PIPELINE

Program Development Stage Status

Our two psilocybin-based drug candidates focus on treating obesity and weight management


12

IP PORTFOLIO SURROUNDS THE SPECTRUM OF WEIGHT MANAGEMENT CONDITIONS• Global patent portfolio with potential

rights in 152 countries including the US

• 11 US provisional and 4 PCT applications filed to date

• Claims covering methods of treating obesity and weight management conditions

• R&D activities will support additional applications with at least 5 planned

• Anticipated Protection Expiry: 2041

Psilocin*, Psilocybin*

4-SH-dimethyltryptamine*

1-methylpsilocin*

4-fluoro-N,N-dimethyltryptamine*

O-acetylpsilocin

4-hydroxy-N-methyl-N-isopropyltryptamine*

4-hydroxy-N-methyl-N-ethyltryptamine*

LSD**, LSA**, DMT**

COMPOUNDS COVERED

Aiding Weight Loss

Obesity

Compulsive Eating Disorder

Diet Alteration

Reduction of Food Cravings

Decreasing Food Intake

Complications Associated with Obesity

TREATMENTS COVERED

* NeonMind owns 100% of intellectual property** NeonMind owns 80% of intellectual property, Translational Life Sciences Inc. (research collaborator) owns remaining 20%


13

GROWING DEMAND FOR MENTAL HEALTH TREATMENTS AND SPECIALTY MENTAL HEALTH CLINICS

MENTAL HEALTH CONDITIONS CONTINUE TO BE A GLOBAL HEALTH ISSUE

STRONG GROWTH TRENDS IN MENTAL DISORDER TREATMENT MARKET2

MASSIVE GLOBAL MARKET FOR GLOBAL MENTAL DISORDER TREATMENT2

284MAnxiety, PTSD

264MDepression

Global Population of Affected Individuals1

1. Ritchie 2018, Our World in Data. 2. Coherent Market Insights, 2020. Mental Disorder Treatment Market Analysis. 3. Estimates from company marketing materials. Assumes average patient completes treatment program with 6 drug sessions and will be treated annually.

US $48.8B by 2022

6.6% CAGRForecast period

(2020-2027)

MEDICALSERVICES DIVISION


14

PSYCHEDELICS HAVE POTENTIAL TO ADDRESS LARGE MEDICAL NEED BUT REQUIRE SPECIALIZED TREATMENT INFRASTRUCTURE

PSYCHEDELIC DRUG DEVELOMENT PROGRAMS ARE NEARING APPROVAL1

Psychedelic Indication Est. Approval

MDMA PTSD 2023+

Psilocybin TRD 2025+

Psilocybin MDD 2025+

1. Company marketing materials and management estimates.

PSYCHEDELIC TREATMENTS WILL REQUIRE SPECIALIZED CLINICS INFRASTRUCTURE

● Psychedelics will require administration under direct supervision in a controlled setting

● Clinics infrastructure buildout still in infancy

● Opportunity for NeonMind to take leadership in specialized clinics providing psychedelic treatments



15

• Establishing NeonMind-branded specialty mental health clinics in underserved markets; first clinic expected to be announced in 2021

• Incorporating evidence-backed innovative treatments for a variety of mental health needs, including psychedelic treatment modalities

• Assembling a team of experts to become the trusted partner for specialty mental treatments

• Establishing a strategic footprint with early-mover advantage

• Positioned to capitalize on the large and promising pipeline of the new psychedelic therapies, once approved

LAYING THE FOUNDATIONS TO BE THE TRUSTED PARTNER IN TRANSFORMATIONAL MENTAL HEALTH TREATMENTS



NEAR-TERM COMMERCIALIZATIONLeveraging existing proprietary functional food formulations to sell direct-to-consumer on our e-commerce platform.

Initial sales recognized for mushroom-infused coffee products in Canada; plan to launch e-commerce platform in the U.S.

Capturing a segment of global functional mushroom market- forecasted to reach $34.3 billion by 2024*.

CSE: NEON •OTC: NMDBF | 16

https://www.mordorintelligence.com/industry-reports/functional-mushroom-market*NDP food study, “U.S. Consumers’ Desire to Use Food as Medicine is Evidenced by Emerging Superfoods”


https://www.mordorintelligence.com/industry-reports/functional-mushroom-markethttps://www.npd.com/wps/portal/npd/us/news/press-releases/2019/us-consumers-desire-to-use-food-as-medicine-is-evidenced-by-emerging-superfoods/https://www.npd.com/wps/portal/npd/us/news/press-releases/2019/us-consumers-desire-to-use-food-as-medicine-is-evidenced-by-emerging-superfoods/

PRODUCT OFFERINGS


Our range of coffee products are infused with legal medicinal mushrooms such as Lion’s Mane, Turkey Tail, Reishi and Cordyceps.


PROGRESS AND KEY ACHIEVEMENTS

CSE: NEON • FRA: UF6 | 18CSE: NEON • OTC; NMDBF | 18

Established international and US patent applications covering the spectrum of weight management conditions

Pre-clinical study completed demonstrating weight sparing signal for low and high dose-psilocybin regime - 4Q20

Canadian eCommerce launch of four functional mushroom coffee blends for consumer division – 4Q20

Filed four (4) NHP applications with Health Canada to support the launch of consumer products division - 1Q21

US $4.6M raised in January 2021 IPO – 1Q21

Established Medical Services Division to launch NeonMind-branded specialty mental health clinics - 2Q21

19

UPCOMING MILESTONES

CSE: NEON • FRA: 6UF | 19

NeonMind expects to execute on the following key initiatives:● Finalize integrated drug development plan to

define research plan needed to advance both programs through to NDA – 2Q21

● E-commerce U.S. launch – 2Q21

● Preclinical study #2 data: – 3Q21

● Pre-IND meeting with FDA – 4Q21

● Complete design of Phase 2a study with FPI – 4Q21/1Q22

● Launch inaugural NeonMind-branded Specialty Clinic for mental health – 1Q22

MANAGEM

ENT & CONSULTANTS

ROBERT TESSAROLOPRESIDENT & CHIEF EXECUTIVE OFFICER

● Over 25 years of experience in the pharmaceutical industry● Former President, CEO and Director of Mind Medicine Inc.

(NEO:MMED)● Former President & CEO of Cipher Pharmaceuticals Inc.

(TSX:CPH)● Former VP, General Manager Celgene US Inflammation &

Immunology and former President Watson Pharmaceuticals Canada


TREVOR MILLARCHIEF PSYCHEDELIC OFFICER

● Social-entrepreneur advancing the psychedelic movement since 2013

● Board Chairman Multidisciplinary Association of Psychedelic Studies (MAPS) Canada

● Co-Founder and Board Member Canadian Psychedelic Association.

● Founder of Liberty Root Therapy Inc.; featured in the award-winning psychedelic documentary 'DOSED'

RICK HUANGCFO

● CFO of Better Plant Sciences Inc. (CSE: PLNT)● Serves as Chair of the Audit Committee for Datable

Technology Corp. (TSXV: TTM)● Former CFO of Hanwei Energy Services Corp. (TSX: HE)● Former Chair of Governance and member of Audit

Committees at Poydras Gaming Finance Corp. (TSXV: PYD)

CLIVE WARD-ABLEMEDICAL & SCIENTIFIC AFFAIRS CONSULTANT

● Physician and a pharmacist who has worked in the pharmaceutical industry for over 28 years

● Has worked in large and small pharmaceutical and biotechnology companies in Canada, the U.S., UK, Switzerland, and South Africa

● Currently a member of the Board of Directors for Clinical Trials Ontario

● Former member of the Medical & Scientific Advisory Committee of Innovative Medicines Canada.

ERNIE HOVP, CORPORATE DEVELOPMENT

● Over 14 years of development and commercialization

experience in the biopharma and diagnostics industry

● Experience throughout value chain from pre-clinical to

product management

● Success in corporate development including licensing,

M&A, and capital raise

● PhD from Western University

PHILIPPE MARTINDRUG DEVELOPMENT CONSULTANT

● 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of immunology, oncology and neurology.

● Chief of Clinical Development & Operations at BioAtla, Inc.,

● Former Corporate Vice President at Celgene

ADVISORS DR. WILLIAM PANENKAMEMBER, ADVISORY BOARD

● Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.

● Founder and Director, Translational Life Sciences Inc.


DR LAIRD BIRMINGHAMMEMBER, ADVISORY BOARD

● World renowned eating disorder specialist for over 35 years, who has pioneered several new internationally recognized treatments for eating disorders

● Professor at the University of British Columbia, Faculty of Medicine Department of Psychiatry

DR. FRANK RUSSOMEMBER, ADVISORY BOARD

● Professor of Psychology at Ryerson University, Hear the World Research Chair in Music and Emotional Speech.

● Affiliate scientist at the Toronto Rehabilitation Institute, core member of the McMaster Institute for Music and the Mind (MIMM), and adjunct professor at the University of Toronto’s Music and Health Collaboratory (MaHRC).

● Fellow of the Canadian Psychological Association and Massey College, and is a past president of the Canadian Acoustical Association

CHARLES BOULAKIAMEMBER, ADVISORY BOARD

● Over 18 years of experience as a patent lawyer in the preparation and prosecution of patent applications

● Partner of Ridout & Maybee LLP ; practice focus directed towards the preparation and prosecution of patent applications in the biotechnology, chemistry, biofuel, oil and gas and pharmaceutical areas

● Vice-Chair of the AIPPI Standing Committee on Pharma and Biotechnology

DR. ALASDAIR BARRPRINCIPAL INVESTIGATOR

● PhD in Neuropharmacology, post doctoral training at Scripps Institute and drug discovery with Novartis.

● Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, UBC

● Approved by Health Canada to possess psilocybin for NeonMind Preclinical trial

DR. GARCIA-ROMEUMEMBER,ADVISORY BOARD

● Assistant Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine.

● Has conducted more than 90 high-dose psilocybin sessions in the laboratory since 2012

● Founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research.

BOARD OF DIRECTORS


PENNY WHITEEXECUTIVE CHAIRMAN, DIRECTOR, FOUNDER

● Serial entrepreneur with over two decades of experience building companies.

● Recognized in PROFIT Magazine's W100● Co-founder, President and CEO of Better Plant Sciences

Inc. (CSE: PLNT, OTCQB:VEGGF)● Former Director Merus Labs Inc. (TSX:MSL)

JEFF B. SMITHINDEPENDENT DIRECTOR

● Over 30 years of general management experience

● Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies (NYSE:JNJ)

● Co-Founder and CEO of Paragon Vitamins and

● Co-Founder & Partner at Ignite Ventures Studios

KARI RICHARDSONINDEPENDENT DIRECTOR

● Over 15 years practicing as a securities lawyer● Partner of Owen Bird Law; practice focused on mergers

and acquisitions, corporate finance and securities.● Member of the Law Society of New Brunswick since

1997 and a member of the Law Society of British Columbia since 2005.

CAPITAL STRUCTURE

Total Issued and outstanding Shares: 123,127,983

Shares held by Insiders: 58,861,500

Shares subject to Escrow: 46,542,1501

Equity Incentives issued (Options & RSUs): 24,625,597

Average daily trading volume in Canada: 1,019,1492

(1) Shares have been escrowed as required by NI 46-201 Escrow for Initial Public Offerings; released in tranches beginning one month after the Listing Date and ending 3 years after the Listing Date.

(2) As of the close of business on May 28, 2021.

STOCK AND FINANCIAL INFORMATION

CSE: NEON • OTCQB: NMDBF | 23

CASH POSITION

1 As of March 31, 2021.

2 Gross burn rate based on the internal 2021 Budget Plan, excluding anticipated sales from consumer products and unscheduled R&D expenses.

Cash, cash equivalent and short-term investments position of $2.7M1 as of March 31.

Estimated monthly burn rate of $350,0002

24

INVESTMENT SUMMARY❖ Focused on psychedelic drug development program within unique

indication – obesity and weight management

❖ Pre-clinical data supports pursuit of two parallel development tracks: low dose and high dose psilocybin therapeutics

❖ Establishing NeonMind-branded specialty mental health clinics to capitalize on psychedelic-based treatments for mental health disorders

❖ Near-term revenue opportunities with exciting consumer product launches in high growth functional food markets

❖ Led by seasoned management team with expertise in pharmaceuticals, drug development and commercialization


CONTACT

ROB TESSAROLOPresident &

Chief Executive [email protected] +1 416 919 9483

PENNY WHITEExecutive Chairman, Founder & Director

[email protected] +1 604 617 7979


APPENDIX


27

RESURGENCE IN PSYCHEDELICMEDICINE IS JUST BEGINNING● Resurgence in clinical psychedelic use enabled by more

progressive regulatory framework

● Growth in clinical studies, in particularly psilocybin1

● Regulators recognize clinical value, granting Fast Track, Breakthrough Therapy, and Priority Review

● Recent FDA approval of SPRAVATO® (esketamine) for treatment-resistant depression○ Est. > US$1B in peak sales2

● Big Pharma’s interest and involvement:○ J&J (esketamine), AbbVie (rapastinel)

BREAKTHROUGH THERAPY

Esketamine Rapastinel MDMA Psilocybin

MDMAPsilocybin

1. Tullis 2021, Nature News. 2. FiercePharma 2019.

Clinical Trials in Psychiatric, Addiction, and Eating Disorders1


28

SURGE IN COMPANIES CAPITALIZING ON PSYCHEDELICS WITH STRONG SUPPORT FROM INVESTMENT COMMUNITY● 15+ public companies totaling over US$5.0B in market cap involved in psychedelics1

● 200% market cap growth over past year2,3

● Over US$700.0M in capital raised in last 12 months4

● Company formation has occurred throughout psychedelic value chain

1. Horizons Psychedelic Stock Index ETF (PSYK) for list of top companies. 2. Since H2 2020. 3.Company filings. 4. As of Feb 19, 2021.

CONTRACT MANUFACTURING DRUG DEVELOPMENT MEDICAL CLINIC CONSUMER/ WELLNESS


29

EFFECTIVE OPTIONS ARE STILL NEEDEDTO ADDRESS THE OBESITY EPIDEMIC

1.Blumenthal 2018 Commonwealth Fund. 2. CDC Oct 2013, Prevalence of Obesity Among Adults. 3. Masters 2013, Am J Public Health. 4. Finkelstein 2009, Health Aff. 5. American Society for Metabolic and Bariatric Surgery 2020.

Percentage of Adult Population Considered Obese1

GROWING US PUBLIC HEALTH CRISIS 2,3 MASSIVE COST TO SOCIETY4 MAJOR UNMET NEED

Estimate of US Bariatric Surgeries5

300,000

250,000

200,000

150,000

100,000

50,000

0

2011 2012 2013 2014 2015 2016 2017 2018

252,000

20% > $140B USEstimated Annual Spend on Obesity-related Medical Care

Despite Current Options, Bariatric Surgeries Continue to Rise5of Adult Deaths Associated to being Overweight or Obese

of Adults are Obese35%


30

OBESITY: MUCH MORE THAN JUST EXCESS WEIGHTObesity tied to many comorbidities1 such as: • Type 2 diabetes, metabolic syndrome, gallbladder disease• Hyperlipidemia, hypertension, cardiovascular disease,

non-alcoholic fatty liver disease, • Osteoarthritis• Cancer

Associated with mental health disorders: • Depression, anxiety, PTSD, OCD

People living with obesity face substantial bias and stigma

1. Wharton et al. 2020, Canadian Adult Obesity Clinical Practice Guidelines. 2. Xu 2018, JAMA Netw Open. 3. Apple 2018, Obes Sci Pract.

“There is a recognition that obesity management should beabout improved health and well-being, and not just weight loss”From Canadian Obesity Clinical Practice Guidelines 2020

SURVIVAL CURVE FOR DIFFERENT BMI CLASSES2,3


31

DURABLE EFFICACY IS LACKING

Weight Loss from Drug Therapy Consistently Hits a Plateau within a Year

Oftentimes Weight Loss Stops With Discontinuation of Drug Therapy and Weight Gain Can Occur While on Drug Therapy

Pi-Sunyer 2015, NEJM. Wadden 2021, JAMA Network. Davidson 1999 JAMA.CSE: NEON • OTC: NMDBF | 31

32

LOW PERSISTENCE OF USE IN REAL WORLD ALSO DIMINISHES EFFICACY• Saxenda is one of the more efficacious drugs

• Despite this, persistent use dramatically decreases over time

• Less than 10% stay on after one year

• Even with a patient support program, persistent use drops significantly

• Similar findings are seen with other drugs

Wharton 2020, Obes Sci Pract. CSE: NEON • OTC: NMDBF | 32

R&D COLLABORATIONSTRANSLATIONAL LIFE SCIENCES

NeonMind has acquired approximately 18% of TLS, a start-up biotechnology company focused on developing proprietary formulations containing restricted substances such as psilocybin and cannabis.

TLS was engaged to design NeonMind’s psilocybin preclinical research. The TLS team has vast experience designing and conducting preclinical and clinical trials using a restricted substance.

Dr. William Panenka is the founder of TLS as well as a member of NeonMind’s Advisory Board.

CERTARA INC.

Certara ® , the global leader in model-informed drug development was engaged to provide strategic integrated drug development support for the investigation of NeonMind’s psilocybin-based drug candidates for the treatment of obesity.

Certara provides biosimulation software to transform traditional biopharmaceutical R&D with a scientific team that has more than 3,500 years of collective drug discovery and development experience.

Since 2014, 90% of new drug and biologic approvals by the US FDA have beenreceived by Certara’s customers.

CSE: NEON • OTC; NMDBF | 33

34

MEDIA COVERAGE

CONFERENCEMay 4 - 5

https://www.psychedelics-conference.com/

PSYCHEDELIC FINANCE INTERVIEWFebruary 2 https://www.psychedelicfinance.com/articles/rob-tessarolo-president-ceo-neonmind-biosciences

REDDIT Q&AFebruary 23

https://www.reddit.com/r/shroomstocks/comments/llazkv/hi_this_is_rob_tessarolo_and_trevor_millar_from/

PSYCHEDELIC SPOTLIGHT Can Psilocybin Cure Obesity? NeonMind Biosciences Thinks it Just Might

https://psychedelicspotlight.com/can-psilocybin-cure-obesity/

NeonMind Takes Psilocybin Therapy Public

https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/

PSYCHEDELICS TODAYPT230 Penny White of NeonMind Biosciences

https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/

THE EYEOPENER: Ryerson professor to lead music-based development program with psychedelic research

https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/

https://psychedelicspotlight.com/can-psilocybin-cure-obesity/https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/https://psychedelicspotlight.com/neonmind-takes-psilocybin-therapy-public/https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/https://psychedelicstoday.com/2021/02/09/pt230-penny-white-of-neonmind-biosciences/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/https://theeyeopener.com/2021/02/ryerson-professor-to-lead-music-based-development-program-with-psychedelic-research/

cse: neon · 2021. 2. 4. · on may 21, 2020, mind medicine (mindmed) inc. announced that it had...

Documents